XNCR
Companies
NASDAQ
Xencor Inc.
Health Care
$8.36
-$14.63 (-63.64%)
Price Chart
Overview
About XNCR
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Market Cap
$1.3B
Volume
8.1M
Avg. Volume
7.1M
P/E Ratio
-2.2296512
Dividend Yield
0.00%
Employees
290.0
Company Information
Latest News for XNCR
Risk & Correlation Analysis
Market Correlation
1.37
High Correlation
Volatility
High (0.50)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, XNCR shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.3B
Volume8.1M
P/E Ratio-2.23
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 27, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025